Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06484920 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
A Phase 2 study of B-cell Lymphoma and Refractory Non-Hodgkin Lymphoma, sponsored by Rita Assi.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT06484920 is a Phase 2 study of B-cell Lymphoma and Refractory Non-Hodgkin Lymphoma that is actively recruiting participants, run by Rita Assi. The registered enrollment target is 24 participants, below the 90-participant average among 38 other B-cell Lymphoma trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06484920, a Phase 2 study of B-cell Lymphoma and Refractory Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Rita Assi.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG ATRA
Study Locations (2)
Indiana
- Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
- Sidney and Lois Eskenazi Hospital - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-11-18 |
| Est. Completion | 2029-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06484920
The ClinicalTrials.gov registry entry for NCT06484920 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 38 other B-cell Lymphoma trials with a reported enrollment target (73% lower). The listed sponsor is Rita Assi, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with B-cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06484920 reports 2 study locations spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT06484920 about?
NCT06484920 is a clinical study titled "A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL". This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.
What is the current status of trial NCT06484920?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2024-11-18. Estimated completion is 2029-09.
What conditions does trial NCT06484920 study?
This clinical trial studies the following conditions: B-cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin Lymphoma.
What interventions are being tested in trial NCT06484920?
The interventions under investigation include: Pembrolizumab (DRUG), ATRA (DRUG).
Who is sponsoring clinical trial NCT06484920?
This trial is sponsored by Rita Assi, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06484920 being conducted?
This trial has 2 study locations across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
RECRUITING · Phase 2
-
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
RECRUITING · Phase 2
-
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
RECRUITING · Phase 2
-
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
RECRUITING · Phase 2
-
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.